Biotechnology Division of Diagnostic Medical Systems S.A. agreed to acquire Hybrigenics Société Anonyme (ENXTPA:ALHYG) in a reverse merger transaction on September 17, 2019. Pursuant to the terms, Hybrigenics Société Anonyme will acquire Biotechnology Division of Diagnostic Medical Systems and in return will issue 80% stake. The transaction is subject to approval from shareholders of Hybrigenics Société Anonyme in a shareholder meeting scheduled on September 20, 2019. The transaction is approved by shareholders of Diagnostic Medical Systems. The transaction was approved by the shareholders of Hybrigenics at a combined general meeting on September 16 and 20, 2019 respectively. As of October 8, 2019, the Autorité des marchés financiers (AMF) provided a a derogation to the obligation to submit a public offer for the shares of Hybrigenics. Atout Capital acted as financial advisor to DMS. Touzet Bocquet & Associés and Jean-François Tramoni-Venerandi acted as legal advisors of DMS.

Biotechnology Division of Diagnostic Medical Systems S.A. completed the acquisition of Hybrigenics Société Anonyme (ENXTPA:ALHYG) in a reverse merger transaction on October 14, 2019. Hybrigenics has issued 187 million shares and has a total capital of 233.77 million shares. These new shares will be assimilated to the old Hybrigenics shares admitted to trading on Euronext Growth in Paris on October 17, 2019, on the same quotation line as the existing shares. Hybrigenics' Board of Directors consists of Jean-Paul Ansel, Chairman of the Board of Directors and also Chairman and Chief Executive Officer of DMS Group, See-Nuan Simonyi, Director of DMS and Philippe Nérin, President of SATT AxLR. The transaction has been approved in the Board meetings of Diagnostic Medical and Hybrigenics.